Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Clenbuterol hydrochloride by CuraSen Therapeutics for Parkinson's Disease: Likelihood of Approval
Clenbuterol hydrochloride is under clinical development by CuraSen Therapeutics and currently in Phase II for Parkinson's Disease. According to GlobalData,...
(CST-2032 + nadolol) by CuraSen Therapeutics for Dementia: Likelihood of Approval
(CST-2032 + nadolol) is under clinical development by CuraSen Therapeutics and currently in Phase II for Dementia. According to GlobalData,...
(CST-2032 + nadolol) by CuraSen Therapeutics for Mild Cognitive Impairment: Likelihood of Approval
(CST-2032 + nadolol) is under clinical development by CuraSen Therapeutics and currently in Phase II for Mild Cognitive Impairment. According...
(CST-2032 + nadolol) by CuraSen Therapeutics for Dementia Associated With Alzheimer's Disease: Likelihood of Approval
(CST-2032 + nadolol) is under clinical development by CuraSen Therapeutics and currently in Phase II for Dementia Associated With Alzheimer's...
Clenbuterol hydrochloride by CuraSen Therapeutics for Parkinson's Disease: Likelihood of Approval
Clenbuterol hydrochloride is under clinical development by CuraSen Therapeutics and currently in Phase II for Parkinson's Disease. According to GlobalData,...
CST-2140 by CuraSen Therapeutics for Orthostatic Hypotension: Likelihood of Approval
CST-2140 is under clinical development by CuraSen Therapeutics and currently in Phase I for Orthostatic Hypotension. According to GlobalData, Phase...